Literature DB >> 11688966

Tumor cells as the origin of elevated serum alpha1,3fucosyltransferase in association with malignancy.

T Asao1, H Kuwano, J Nakamura, A Okamura, E G Berger, K L Matta, S Yazawa.   

Abstract

We have previously reported that the elevated activities of serum alpha 1,3fucosyltransferase reverted to normal levels after curative removal of the tumors. To determine the origin of elevated serum alpha 1,3fucosyltransferase, blood samples were obtained from both the drainage vein and the artery in patients with different stages of colorectal cancer at surgery. The enzyme levels in all samples from the drainage vein were found to be higher than the levels in the artery that fed the tumor. Hence, the origin of elevated alpha1,3fucosyltransferase in serum was thought to be the tumor rather than the liver that is the normal source of serum alpha1,3fucosyltransferase. When serum samples not only from colorectal cancer patients but also from patients with gastric, liver, lung, pancreas, bladder and esophagus cancer were treated with anti-FUTVI antibody, the measured activities of alpha1,3fucosyltransferase were markedly reduced. Further, secretion of alpha1,3fucosyltransferase from human colorectal carcinoma cells was also detected in the culture medium by Western immuno-blot analysis with anti-FUTVI antibody.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11688966     DOI: 10.1023/a:1011967119736

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  29 in total

Review 1.  Carbohydrate composition and immunomodulatory activity of different glycoforms of alpha1-acid glycoprotein.

Authors:  S D Shiyan; N V Bovin
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 2.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

3.  Effects of monocytic products, recombinant interleukin-1, and recombinant interleukin-6 on glycosylation of alpha 1-acid glycoprotein: studies with primary human hepatocyte cultures and rats.

Authors:  O Pos; H J Moshage; S H Yap; J P Snieders; L A Aarden; J van Gool; W Boers; A M Brugman; W van Dijk
Journal:  Inflammation       Date:  1989-08       Impact factor: 4.092

4.  Trafficking and localization studies of recombinant alpha1, 3-fucosyltransferase VI stably expressed in CHO cells.

Authors:  L Borsig; A G Katopodis; B R Bowen; E G Berger
Journal:  Glycobiology       Date:  1998-03       Impact factor: 4.313

5.  Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Correlation with histopathologic variables.

Authors:  Y Tabuchi; H Deguchi; K Imanishi; Y Saitoh
Journal:  Cancer       Date:  1987-04-01       Impact factor: 6.860

6.  Carcinoembryonic antigen and carbohydrate antigen 19-9 levels of peripheral and draining venous blood in colorectal cancer patients. Correlation with histopathologic and immunohistochemical variables.

Authors:  Y Tabuchi; H Deguchi; Y Saitoh
Journal:  Cancer       Date:  1988-10-15       Impact factor: 6.860

7.  Increased plasma alpha (1 --> 3)-L-fucosyltransferase activities in patients with hepatocellular carcinoma.

Authors:  T Hada; K Fukui; M Ohno; S Akamatsu; S Yazawa; K Enomoto; K Yamaguchi; Y Matsuda; Y Amuro; N Yamanaka
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

8.  Use of N-acetyl-2'-O-methyllactosamine as a specific acceptor for the determination of alpha-L-(1----3)-fucosyltransferase in human serum.

Authors:  R Madiyalakan; S Yazawa; S A Abbas; J J Barlow; K L Matta
Journal:  Anal Biochem       Date:  1986-01       Impact factor: 3.365

9.  Genetic and enzymatic evidence for Lewis enzyme expression in Lewis-negative cancer patients.

Authors:  S Yazawa; S Nishihara; H Iwasaki; T Asao; Y Nagamachi; K L Matta; H Narimatsu
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

10.  Aberrant alpha 1-->2fucosyltransferases found in human colorectal carcinoma involved in the accumulation of Leb and Y antigens in colorectal tumors.

Authors:  S Yazawa; J Nakamura; T Asao; Y Nagamachi; M Sagi; K L Matta; T Tachikawa; M Akamatsu
Journal:  Jpn J Cancer Res       Date:  1993-09
View more
  2 in total

1.  N-Acetylglucosamine 6-O-sulfotransferase-2 as a tumor marker for uterine cervical and corpus cancer.

Authors:  Akira Seko; Fumio Kataoka; Daisuke Aoki; Masaru Sakamoto; Toshiaki Nakamura; Masayuki Hatae; Suguru Yonezawa; Katsuko Yamashita
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

2.  Fucosylated Glycans in α1-Acid Glycoprotein for Monitoring Treatment Outcomes and Prognosis of Cancer Patients.

Authors:  Shin Yazawa; Ryo Takahashi; Takehiko Yokobori; Rie Sano; Akira Mogi; Abby R Saniabadi; Hiroyuki Kuwano; Takayuki Asao
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.